Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70394 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Takuma Yamai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Autism Spectrum Disorder. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Children with autism spectrum disorder (ASD) often experience significant distress during medical procedures, which can limit access to optimal treatments such as biologic therapy for atopic dermatitis (AD). However, practical strategies for initiating injectable biologic therapy without physical restraint in this population remain poorly described. We report a case demonstrating a structured and reproducible approach that enabled restraint‐free initiation of dupilumab in a child with ASD. A 6‐year‐old boy with moderate‐to‐severe AD and comorbid ASD had a history of severe procedural avoidance requiring physical restraint for blood sampling and vaccinations. He was admitted for remission induction and consideration of dupilumab therapy. A Certified Child Life Specialist conducted an individualized intervention beginning early in hospitalization, including assessment of sensory sensitivities, visual preparation, environmental modification, and procedural rehearsal. On hospital Day 11, the first subcutaneous injection of dupilumab was successfully administered without physical restraint or additional staff assistance. A coordinated multidisciplinary strategy was implemented, including minimized sensory stimulation, predefined team roles, and distraction techniques. No adverse events occurred, and subsequent injections were performed smoothly in the outpatient setting without further specialized support. This case provides a practical and reproducible framework for overcoming procedural barriers and safely initiating biologic therapy in children with ASD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
- Child Life Services, National Center for Child Health and Development, Tokyo, Japan.
ORCID-Profile: Takuma Yamai, Kiwako Yamamoto-Hanada, Shungo Yamamoto, Chisato Jimbo, Tomoki Yaguchi, Kotaro Umezawa, Kenji Toyokuni, Mitsuru Kubota, Tatsuki Fukuie
Zitieren
APA
Yamai, T., Yamamoto-Hanada, K., Yonemichi, H., Yamamoto, S., Jimbo, C., Yaguchi, T., Suzuki, D., Umezawa, K., Hirai, S., Toyokuni, K., Kubota, M., & Fukuie, T. (2026). Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70394
Vancouver
Yamai T, Yamamoto-Hanada K, Yonemichi H, Yamamoto S, Jimbo C, Yaguchi T, et al. Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70394
BibTeX
@article{Yamai2026,
author = {Yamai, Takuma and Yamamoto-Hanada, Kiwako and Yonemichi, Hiroko and Yamamoto, Shungo and Jimbo, Chisato and Yaguchi, Tomoki and Suzuki, Daichi and Umezawa, Kotaro and Hirai, Seiko and Toyokuni, Kenji and Kubota, Mitsuru and Fukuie, Tatsuki},
title = {Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70394}
}
EUVIMED